Key result
Higher ePWV increased death or major disability at 14 days and 3 months without modifying early antihypertensive therapy.
Why the study?
Whether estimated pulse wave velocity (ePWV) influences the effect of early antihypertensive treatment in acute ischemic stroke remained unclear.
Does estimated pulse wave velocity (ePWV) predict clinical outcomes or modify the effect of early antihypertensive treatment on death or major disability in patients with acute ischemic stroke?
RCT (n=4,058)
Does estimated pulse wave velocity (ePWV) predict clinical outcomes or modify the effect of early antihypertensive treatment on death or major disability in patients with acute ischemic stroke?
Higher admission estimated pulse wave velocity is independently associated with increased risk of death or major disability after acute ischemic stroke, but it does not modify the clinical effect of immediate antihypertensive therapy.
Answers are grounded in this paper and cite their sources.
Elevated ePWV identifies higher-risk acute ischemic stroke patients; extends prognostic evidence without supporting modification of early antihypertensive therapy.
BACKGROUND: Whether estimated pulse wave velocity (ePWV) influences the effect of early antihypertensive treatment in acute ischemic stroke remains unclear. METHODS: This study was a post hoc analysis of the China Antihypertensive Trial in Acute Ischemic Stroke conducted in 2009-2013. ePWV was calculated using age and mean blood pressure on admission. The primary outcome was a composite of death or major disability at 14 days or hospital discharge and 3 months after stroke. We examined the association between ePWV and the primary outcome and tested for the interaction between ePWV and early blood pressure-lowering treatment. RESULTS: Among the 4058 and 3975 participants included in the 14-day or hospital discharge and 3-month analyses, respectively, 1364 (33.6%) and 1001 (25.2%) experienced the composite outcome of death or major disability. The multivariable-adjusted risk ratios (95% CIs) for the highest (≥12.7 m/s) versus lowest ePWV tertile (<11.1 m/s) were 1.23 (1.06-1.43) for the composite outcome of death or major disability and 2.87 (1.10-5.39) for death at 14 days or hospital discharge (P for trend<0.05). At 3 months, the adjusted risk ratios (95% CIs) were 1.41 (1.17-1.70), 3.91 (2.02-7.57), and 2.33 (1.33-4.07) for the composite outcome of death or major disability, death, and vascular events, respectively. There were no significant differences in clinical outcomes between the early antihypertensive treatment and control groups across ePWV tertiles. CONCLUSIONS: : Higher ePWV was associated with worse clinical outcomes after acute ischemic stroke, and ePWV did not modify the effect of early antihypertensive treatment. REGISTRATION: -URL: https://www.clinicaltrials.gov; Unique identifier: NCT01840072.
No takes yet. Share an insight, caveat, or question.
Che et al. (2026) conducted an RCT in Acute ischemic stroke (n=4,058). Highest estimated pulse wave velocity (ePWV ≥12.7 m/s) and early antihypertensive treatment vs. Lowest ePWV tertile (<11.1 m/s) and control group was evaluated on Composite of death or major disability at 14 days or hospital discharge and 3 months after stroke (RR 1.23, 95% CI 1.06-1.43, p=<0.05). Higher ePWV increased death or major disability at 14 days and 3 months without modifying early antihypertensive therapy.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: